Partner introduction - 2. Biomodics

STARDUST partner introductions are a series of interviews profiling each partner in our Project. Today it is Biomodics’ turn.

Biomodics is an independent Danish service and technology provider to the life science industry. With a background in the NKT technology cluster Biomodics ApS was founded in 2010 and holds the patent portfolio for supercritical CO, interpenetrating polymer networks and drug delivery. Biomodics’ core technologies and services include supercriticial fluid processing, functional surfaces and materials for drug delivery, biological nano-sensing and characterization, and imaging core facilities. Biomodics is actively working within the field of IPN networks for the health care sector. This focus includes proprietary technology within hybrid polymers and medical devices. Biomodics has repeatedly been acknowledged in events such as the Eurecan European Venture Contest where an international jury selected Biomodics as the overall winner.

  1. Tell us briefly about STARDUST team and expertise.
    A chain is no stronger than its weakest link. Medical devices fails over and over due to mediocre materials. Materials developed for electric insulation, rainwear, bottles for soft drinks and sailcloth for ships are now used as artificial blood vessels. Of cause such solutions may bypass the immediate health issues e.g. restore blood flow, but these materials cause blood clots, inflammations and infections. However they are tolerated by authorities because no better alternative exists. Biomodics have taken the challenge to tailor materials to not only solve the immediate health issue but also provide sustained biocompatibility for a life-time.

    It would be nonsense to expect the extraordinary out of standard components, therefore we make an effort out of building everything from scratch. Through biomimicking, we get inspired by nature’s own solutions and synthesize nature’s own building blocks. These building blocks can then be used to create superior medical devices with new functionalities and performance. Biomodics offer our materials, services and technologies to the life science industry.

  2. What is your role in the STARDUST project? What is the most exciting thing for you in this project?
    In STARDUST our role is to develop and immobilize a light-triggered drug delivery system for the wireless implantable and independent micro-scale device (200x200x200 µm3). Triggered drug delivery systems typically rely on encapsulation of the drug in an amphiphilic block-copolymer, but such an approach would not be applicable for the micro-scale device due to the limited size restrictions. Instead, we aim at physically binding the drug to the device by intermolecular interactions between the drug and a novel light sensitive material. Light changes the structure of the light sensitive material which in turn weakens the physical bond and releases the drug safely from the surface of the micro-scale device.

  3. What do you hope to achieve with the project? What impact would you like to see?
    A generic light-triggered drug delivery system that can be truly switched on and off. Triggered drug delivery systems, in general, have a certain background release of drug. Our target is a that we can obtain zero background release and decide when, where and how much drug is released. Such a drug delivery system would be the first of its kind and have huge impact on the existing drug delivery market.

  4. What are your results so far? And what are the biggest challenges?
    We have now developed the light-triggered drug delivery system. The next challenge is to immobilize it on the micro-scale device. This requires downscaling of coating techniques.

Linda Wederhorn